

## Johnson & Johnson Innovative Medicine Pipeline Key Events in 2025\*

### POTENTIAL APPROVALS US/EU

US	<b>SIMPONI (golimumab)</b>	✓
EU	Pediatric Ulcerative Colitis (PURSUIT 2)	
✓ EU	<b>STELARA (ustekinumab)</b>	✓
	Pediatric Crohn's Disease (UNITI JR)	
US	<b>TREMFYA (guselkumab)</b>	
	Ulcerative Colitis Subcutaneous Induction (ASTRO)	
✓ US	<b>TREMFYA (guselkumab)</b>	
✓ EU	Crohn's Disease Subcutaneous Induction (GRAVITI)	
US	<b>TREMFYA (guselkumab)</b>	
	Pediatric Psoriasis (PROTOSTAR)	
✓ US	<b>TREMFYA (guselkumab)</b>	
✓ EU	Crohn's Disease (GALAXI)	
✓ EU	<b>TREMFYA (guselkumab)</b>	
	Ulcerative Colitis (QUASAR)	

US	<b>IMAAVY (nipocalimab)</b>	✓
EU	Generalized Myasthenia Gravis (Vivacity MG3)	
US	<b>SPRAVATO (esketamine)</b>	✓
	Treatment Resistant Depression monotherapy (TRD4005)	
US	<b>CAPLYTA (lumateperone)</b>	
	Adjunctive Treatment for Major Depressive Disorder	
US	<b>DARZALEX (daratumumab)</b>	
EU	Smoldering Multiple Myeloma (AQUILA)	
US	<b>DARZALEX (daratumumab)</b>	✓
EU	Frontline multiple myeloma transplant ineligible (CEPHEUS)	
US	<b>TAR-200 (RIS/gemcitabine plus cetrelimab)</b>	
	Non Muscle Invasive Bladder Cancer (SunRISe-1)	
US	<b>RYBREVANT (amivantamab)</b>	✓
EU	Subcutaneous (PALOMA-3)	
EU	<b>IMBRUVICA (ibrutinib)</b>	
	Frontline MCL (Triangle)	
✓ US	<b>IMAAVY (nipocalimab)</b>	
	Generalized Myasthenia Gravis Pediatrics (VIBRANCE MG)	

### PLANNED SUBMISSIONS US/EU

US	<b>nipocalimab</b>	✓
	Warm Autoimmune Hemolytic Anemia (ENERGY)	
✓ EU	<b>TREMFYA (guselkumab)</b>	✓
	Ulcerative Colitis Subcutaneous Induction (ASTRO)	
US	<b>TREMFYA (guselkumab)</b>	
	Psoriatic Arthritis Structural Damage (APEX)	
✓ EU	<b>TREMFYA (guselkumab)</b>	
	Pediatric Psoriasis (PROTOSTAR)	
US	<b>STELARA (ustekinumab)</b>	
EU	Pediatric Ulcerative Colitis (UNIFI JR)	
✓ US	<b>STELARA (ustekinumab)</b>	
	Pediatric Crohn's Disease (UNITI JR)	
US	<b>icotrokinra</b>	
EU	Psoriasis (ICONIC)	

US	<b>TAR-200 (RIS/gemcitabine plus cetrelimab)</b>	✓
	Non Muscle Invasive Bladder Cancer (SunRISe-1)	
US	<b>AKEEGA (niraparib/abiraterone)</b>	✓
EU	M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)	

US	<b>TREMFYA (guselkumab)</b>	✓
	Psoriatic Arthritis Structural Damage (APEX)	

US	<b>TREMFYA (guselkumab)</b>	✓
	Pediatric Psoriasis (PROTOSTAR)	

### POTENTIAL CLINICAL DATA PRESENTATIONS'

#### Phase III

✓	<b>AKEEGA (niraparib/abiraterone)</b>	✓
	M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)	
✓	<b>RYBREVANT / LAZCLUZE</b>	✓
	Non Small Cell Lung Cancer (MARIPOSA Final OS)	
✓	<b>TREMFYA (guselkumab)</b>	✓
	Ulcerative Colitis Subcutaneous Induction (ASTRO)	
✓	<b>TREMFYA (guselkumab)</b>	✓
	Psoriatic Arthritis Structural Damage (APEX)	
✓	<b>TREMFYA (guselkumab)</b>	✓
	Pediatric Psoriasis (PROTOSTAR)	
✓	<b>icotrokinra</b>	✓
	Psoriasis (ICONIC-LEAD)	
✓	<b>icotrokinra</b>	✓
	Psoriasis (ICONIC-TOTAL)	
	<b>icotrokinra</b>	
	Psoriasis (ICONIC-Advance1/2)	
✓	<b>aticaprant</b>	✓
	Adjunctive Treatment for Major Depressive Disorder with Anhedonia (Ventura 1)	
✓	<b>RPGR Gene Therapy</b>	✓
	Retinitis Pigmentosa (LUMEOS)	

#### Phase I/ II

✓	<b>TAR-200 (RIS/gemcitabine plus cetrelimab)</b>	✓
	Non Muscle Invasive Bladder Cancer (SunRISe-1)	
	<b>RYBREVANT (amivantamab)</b>	
	Head and Neck Cancer (ORIGAMI-4)	
✓	<b>TALVEY + TECVAYLI</b>	✓
	Multiple Myeloma Relapsed/Refractory (Redirect-TT-1)	
✓	<b>JNJ-4496</b>	✓
	Hematological Malignancies (LYM1001)	
✓	<b>JNJ-5322</b>	✓
	Multiple Myeloma (MMY1001)	
✓	<b>RYBREVANT (amivantamab)</b>	✓
	Colorectal Cancer (ORIGAMI-1 right-sided)	
✓	<b>JNJ-8343</b>	✓
	Prostate Cancer (PCR1001)	
	<b>JNJ-4804 Co-antibody Therapy</b>	
	Psoriatic Arthritis (AFFINITY)	
	<b>icotrokinra</b>	
	Ulcerative Colitis (ANTHEM)	
	<b>nipocalimab Combination Therapy</b>	
	Rheumatoid Arthritis (DAISY)	

✓ = Achieved



1. In order to be on key events clinical presentation, data must be presented at a major medical meeting.

\*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of July 16, 2025 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.